< News, Press, & Events

Press Release

Congenica Integrates Powerful New Curated Data

FOR IMMEDIATE RELEASE
October 2, 2019 Cambridge, United Kingdom

Congenica Integrates Powerful New Curated Data

Congenica Ltd, a digital health technology company enabling accelerated interpretation of complex genomic data to improve disease diagnosis, has announced significant developments to its software solution, with the integration of powerful new reference data sources, DECIPHER and Mastermind® into its clinical decision support platform.

Congenica® is state-of-the-art software accelerating the interpretation of complex genomic data into actionable information to aid disease diagnosis. The platform is empowering healthcare professionals around the world to work through more cases with greater efficiency, increase diagnostic yield and have greater confidence in their diagnostic decisions.

Next Generation Sequencing (NGS) yields up to five million variants per patient, making it challenging to quickly identify and properly evidence the disease-causing variants. DECIPHER enhances clinical diagnosis by retrieving information from a variety of bioinformatics resources relevant to the variant found in the patient.

Integration of DECIPHER data, containing single nucleotide variants (SNVs) and copy number variants (CNVs), into Congenica both reduces the chance of disease-relevant variants going undetected and improves the assignment of variant pathogenicity to optimise diagnostic yield.

Dr Matthew Hurles, FMedSci, FRS, Head of Human Genetics and Senior Group Leader at Wellcome Sanger Institute and a leader in the Deciphering Developmental Disorders (DDD) and DECIPHER projects: “DECIPHER is an invaluable scientific and clinical resource widely used by the clinical genetics and research community. The integration of DECIPHER curated variants and phenotypes into Congenica will greatly aid the identification of diagnostic variants in patients with rare disorders.

“Ultimately, this will help to establish whether the observed variant is likely causal for the phenotype of the patient, allowing clinical scientists and clinicians to make quicker diagnoses with greater confidence.”

Congenica also announced a partnership with Genomenon® to incorporate its Mastermind® Genomic Search Engine into the Congenica platform. Mastermind contains the largest most up-to-date collection of genomic literature, providing immediate access to the genetic research associated with patient variants.

The addition of Mastermind will enable Congenica users to quickly access the genetic evidence associated with their patients’ variants, shortening the search time required to clinically interpret a variant and support its pathogenicity.

DECIPHER and Mastermind data will be available to all Congenica GRCh37 and GRCh38 customers, including the UK’s National Health Service (NHS) as part of Congenica’s arrangement as the exclusivedecision support platform provider for the NHS Genomic Medicine Service.

Mike Klein, CEO of Genomenon: “We’re thrilled to partner with Congenica to put the most comprehensive and up-to-date genetic research in the hands of geneticists making clinical diagnoses. Our relationship extends Mastermind’s global reach, and coupled with Congenica, provides significant value in cutting turnaround time and increasing diagnostic yield for genetic labs.”

David Atkins, CEO of Congenica: “The addition of DECIPHER and Mastermind significantly enhances the already comprehensive range of data sources available in Congenica. We are committed to empowering healthcare professionals everywhere with access to the best reference datasets in a single platform so that Congenica users can make better diagnostic decisions, faster and with complete confidence, to improve the lives of patients and their families.”

About
Genomenon

Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.

About
Congenica

Congenica is a digital health technology company with the world’s leading clinical decision support platform for accelerated genomic data interpretation. Congenica software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients and their families.

Genetic diseases are technically difficult to diagnose, and patients often spend years waiting for a diagnosis. Congenica convert genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalized care.

Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica is headquartered in Cambridge, UK, with a global footprint across the US and China. The Congenica platform is validated by the pivotal Genomics England 100,000 Genomes Project and is the exclusive clinical interpretation partner for the NHS Genomic Medicine Service.

For more information, visit congenica.com.

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.